Lipella pharmaceuticals abstract on oral lichen planus treatment accepted for podium presentation at 2025 aaom/eaom international meeting conference on “global transformation in oral medicine”

Joint meeting to be held in las vegas, may 14-17 presentation will be delivered by dr. alessandro villa of miami cancer institute topline study results demonstrate clinically meaningful improvements in olp visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity pittsburgh, april 23, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) ("lipella," "we," "our," or the "company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on lp-10 for the treatment of oral lichen planus (olp) has been accepted for podium presentation at the 2025 joint international meeting of the american academy of oral medicine (aaom) and european association of oral medicine (eaom). the meeting will take place may 14–17 in las vegas.
LIPO Ratings Summary
LIPO Quant Ranking